Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma

Oncology

Volumn 73, Issue 1-2, 2008, Pages 104-111

  Hasegawa, Yasuhisa ^a   Goto, Mitsuo ^d   Hanai, Nobuhiro ^a   Ijichi, Kei ^b   Terada, Akihiro ^a   Hyodo, Ikuo ^a   Ogawa, Tetsuya ^a   Fukushima, Masakazu ^c  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

^d UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

Author keywords

5 Fluorouracil; Chemosensitivity, in vitro; Cisplatin; Epidermal growth factor receptor; Head and neck squamous cell carcinoma; HER 2; Real time RT PCR

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; MESSENGER RNA; TUMOR MARKER;

ARTICLE; BIOASSAY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HEAD AND NECK CANCER; HISTOCULTURE DRUG RESPONSE ASSAY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MULTIGENE FAMILY; PHARMACODYNAMICS; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 41549168296     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000120998     Document Type: Article

References (41)

1. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-899.
2. Paccagnella A, Orlando A, Marchiori C, et al: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-272.
3. Kartalou M, Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res 2001;478:23-43.
4. Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-1302.
5. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-1594.
6. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-3968.
7. Grandis JR, Melhem MF, Gooding WE, et al: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-832.
8. Dyson N: The regulation of E2F by pRBfamily proteins. Genes Dev 1998;12:2245-2262.
9. DeGregori J, Leone G, Ohtani K, Miron A, Nevins JR: E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev 1995;9:2873-2887.
10. Field SJ, Tsai FY, Kuo F, et al: E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996;85:549-561.
11. Volm M: Multidrug resistance and its reversal. Anticancer Res 1998;18:2905-2917.
12. Ferry KV, Hamilton TC, Johnson SW: Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000;60:1305-1313.
13. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94:703-708.
14. Mackey JR, Yao SY, Smith KM, et al: Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 1999;91:1876-1881.
15. Mackey JR, Mani RS, Selner M, et al: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998;58:4349-4357.
16. Hasegawa Y, Goto M, Hanai N, et al: Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 2007;43:749-756.
17. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
18. Press MF, Pike MC, Hung G, et al: Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994;54:5675-5682.
19. Beckhardt RN, Kiyokawa N, Xi L, et al: HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995;121:1265-1270.
20. Ibrahim SO, Vasstrand EN, Liavaag PG, Johannessen AC, Lillehaug JR: Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res 1997;17:4539-4546.
21. Hengstler JG, Lange J, Kett A, et al: Contribution of c-erbB-2 and topoisomerase IIα to chemoresistance in ovarian cancer. Cancer Res 1999;59:3206-3214.
22. Zhang L, Hung MC: Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 1996;12:571-576.
23. Hung MC, Lau YK: Basic science of HER-2/neu: a review. Semin Oncol 1999;26:51-59.
24. Albanell J, Codony-Servat J, Rojo F, et al: Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001;61:6500-6510.
25. Prigent SA, Lemoine NR: The type 1 (EGFRrelated) family of growth factor receptors and their ligands. Prog Growth Factor Res 1992;4:1-24.
26. Pomerantz RG, Grandis JR: The role of epidermal growth factor receptor in head and neck squamous cell carcinoma. Curr Oncol Rep 2003;5:140-146.
27. Mendelsohn J, Fan Z: Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997;89:341-343.
28. Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM: Both farnesylated and geranyl-geranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem 2000;275:17974-17978.
29. Jiang K, Delarue FL, Sebti SM: EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene 2004;23:1136-1145.
30. Ralhan R, Swain RK, Agarwal S, et al: P-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosis. Int J Cancer 1999;84:80-85.
31. Dannenberg AJ, Altorki NK, Boyle JO, et al: Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544-551.
32. Gallo O, Franchi A, Magnelli L, et al: Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001;3:53-61.
33. Yang HL, Dong YB, Elliott MJ, Liu TJ, McMasters KM: Caspase activation and changes in Bcl-2 family member protein expression associated with E2F-1-mediated apoptosis in human esophageal cancer cells. Clin Cancer Res 2000;6:1579-1589.
34. Metzger R, Leichman CG, Danenberg KD, et al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-316.
35. Koberle B, Masters JR, Hartley JA, Wood RD: Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999;9:273-276.
36. Cheng L, Sturgis EM, Eicher SA, Spitz MR, Wei Q: Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 2002;94:393-397.
37. Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994;54:4313-4320.
38. Yellin SA, Davidson BJ, Pinto JT, Sacks PG, Qiao C, Schantz SP: Relationship of glutathione and glutathione-S-transferase to cisplatin sensitivity in human head and neck squamous carcinoma cell lines. Cancer Lett 1994;85:223-232.
39. Boku N, Chin K, Hosokawa K, et al: Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cisplatinum. Clin Cancer Res 1998;4:1469-1474.
40. Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, Peters GJ: Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 1995;31A:2335-2340.
41. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-8654.